The introduction of recombinant human EPO transformed anemia management by reducing the need for transfusions and improving patient outcomes (Barbieri et al., 2016a; Bazeley and Wish, 2019; Ifudu et al., 1995; Drüeke and Parfrey, 2012; Анемії, 2012). This evidence concerns the gene EPO and anemia.